. Author manuscript; available in PMC: 2021 Dec 21.

Published in final edited form as: Anticancer Res. 2021 Sep 1;41(9):4215–4228. doi: 10.21873/anticanres.15226

Table I.

Cytotoxicity of sorafenib, CFM 4.16 and Tel either alone or in combination in non-small cell lung cancer (NSCLC) and drug resistant NSCLC cells.

Treatment	HCC827		HCC827-ERL-R		H1975		ROC-Res-H1975
Treatment	2D	3D	2D	3D	2D	3D	2D	3D
Sorafenib IC₅₀ (μM	6.3±0.3	36.3±1.8	15.7±0.8	58.7±2.9	17.1±0.4	55.1±2.8	18.3±0.9	58.3±2.9
CFM 4.16 IC₅₀ (μM)	21±1.0	47.7±2.4	21±1.1	52.6±2.6	25±1.3	49.7±2.5	27±1.4	55.6±2.8
Tel IC₅₀ (μM)	53±2.6	88.9±4.4	51±2.6	85.7±4.3	62±3.1	83.5±4.2	64±2.7	81.6±4.1
CFM 4.16 (10 μM) + Sorafenib IC₅₀ (μM)	3.2±0.2	16.6±0.8	3.8±0.2	21.6±1.1	6.7±0.3	19.9±1.0	16.7±0.2	21.3±1.1
CFM 4.16 (10 μM) + Tel (25 μM) + Sorafenib IC₅₀ (μM)	3.1±0.1	8.9±0.4	4.04±0.1	6.7±0.3	6.6±0.2	7.4±0.4	17.4±0.1	11.2±0.6

All the data (IC₅₀ values) shown are representative of three independent experiments and expressed as mean±SEM. Tel: Telmisartan; CFM 4.16: CARP-1 functional mimetic 4.16; μM: Micromolar; IC₅₀: Concentration of a drug that is required for 50% inhibition in vitro; HCC827-ERL-R: erlotinib resistant HCC827 cells; ROC-Res-H1975: Rociletinib resistant H1975 cells.